These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


162 related items for PubMed ID: 22242967

  • 21. The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers.
    Miller AK, DiCicco RA, Freed MI.
    Clin Ther; 2002 Jul; 24(7):1062-71. PubMed ID: 12182252
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Effect of rifampicin on the pharmacokinetics of pioglitazone.
    Jaakkola T, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ.
    Br J Clin Pharmacol; 2006 Jan; 61(1):70-8. PubMed ID: 16390353
    [Abstract] [Full Text] [Related]

  • 27. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
    Nguyen L, Holland J, Miles D, Engel C, Benrimoh N, O'Reilly T, Lacy S.
    J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone.
    Tornio A, Niemi M, Neuvonen PJ, Backman JT.
    Drug Metab Dispos; 2008 Jan; 36(1):73-80. PubMed ID: 17913794
    [Abstract] [Full Text] [Related]

  • 31. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects.
    Mistry GC, Bergman AJ, Luo WL, Cilissen C, Haazen W, Davies MJ, Gottesdiener KM, Wagner JA, Herman GA.
    J Clin Pharmacol; 2007 Feb; 47(2):159-64. PubMed ID: 17244766
    [Abstract] [Full Text] [Related]

  • 32. Lack of Impact by SCY-078, a First-in-Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug-Drug Interactions.
    Wring S, Murphy G, Atiee G, Corr C, Hyman M, Willett M, Angulo D.
    J Clin Pharmacol; 2018 Oct; 58(10):1305-1313. PubMed ID: 29746713
    [Abstract] [Full Text] [Related]

  • 33. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
    Khosravan R, Kukulka MJ, Wu JT, Joseph-Ridge N, Vernillet L.
    J Clin Pharmacol; 2008 Sep; 48(9):1014-24. PubMed ID: 18635756
    [Abstract] [Full Text] [Related]

  • 34. Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers.
    Inglis AM, Miller AK, Culkin KT, Finnerty D, Patterson SD, Jorkasky DK, Freed MI.
    J Clin Pharmacol; 2001 Jun; 41(6):683-90. PubMed ID: 11402638
    [Abstract] [Full Text] [Related]

  • 35. Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency.
    Chapelsky MC, Thompson-Culkin K, Miller AK, Sack M, Blum R, Freed MI.
    J Clin Pharmacol; 2003 Mar; 43(3):252-9. PubMed ID: 12638393
    [Abstract] [Full Text] [Related]

  • 36. Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase.
    Grabowski B, Khosravan R, Wu JT, Vernillet L, Lademacher C.
    Br J Clin Pharmacol; 2010 Jul; 70(1):57-64. PubMed ID: 20642548
    [Abstract] [Full Text] [Related]

  • 37. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
    Khosravan R, Grabowski BA, Wu JT, Joseph-Ridge N, Vernillet L.
    Clin Pharmacokinet; 2006 Jul; 45(8):821-41. PubMed ID: 16884320
    [Abstract] [Full Text] [Related]

  • 38. Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers.
    Aquilante CL, Wempe MF, Spencer SH, Kosmiski LA, Predhomme JA, Sidhom MS.
    Pharmacotherapy; 2013 Sep; 33(9):1000-7. PubMed ID: 23712614
    [Abstract] [Full Text] [Related]

  • 39. Effect of Cytochrome P450 2C8*3 on the Population Pharmacokinetics of Pioglitazone in Healthy Caucasian Volunteers.
    Kadam R, Bourne D, Kompella U, Aquilante C.
    Biol Pharm Bull; 2013 Sep; 36(2):245-51. PubMed ID: 23370354
    [Abstract] [Full Text] [Related]

  • 40. Prediction of inter-individual variability on the pharmacokinetics of CYP2C8 substrates in human.
    Haraya K, Kato M, Chiba K, Sugiyama Y.
    Drug Metab Pharmacokinet; 2017 Dec; 32(6):277-285. PubMed ID: 29174535
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 9.